WO2012125408A8 - Pegylated apelin and uses thereof - Google Patents

Pegylated apelin and uses thereof Download PDF

Info

Publication number
WO2012125408A8
WO2012125408A8 PCT/US2012/028298 US2012028298W WO2012125408A8 WO 2012125408 A8 WO2012125408 A8 WO 2012125408A8 US 2012028298 W US2012028298 W US 2012028298W WO 2012125408 A8 WO2012125408 A8 WO 2012125408A8
Authority
WO
WIPO (PCT)
Prior art keywords
apelin
pegylated apelin
pegylated
disease
treating
Prior art date
Application number
PCT/US2012/028298
Other languages
French (fr)
Other versions
WO2012125408A1 (en
Inventor
Zhiqiang JIA
Lihui HOU
Clark Q. Pan
Geoffrey Y. Akita
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US14/004,377 priority Critical patent/US20140142049A1/en
Priority to AU2012229336A priority patent/AU2012229336B2/en
Priority to EP12757055.4A priority patent/EP2683360B1/en
Priority to SI201230560A priority patent/SI2683360T1/en
Priority to CA2829693A priority patent/CA2829693C/en
Priority to DK12757055.4T priority patent/DK2683360T3/en
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Priority to ES12757055.4T priority patent/ES2573337T3/en
Publication of WO2012125408A1 publication Critical patent/WO2012125408A1/en
Priority to HRP20160547TT priority patent/HRP20160547T1/en
Priority to CY20161100447T priority patent/CY1117654T1/en
Priority to AU2017202919A priority patent/AU2017202919B2/en
Publication of WO2012125408A8 publication Critical patent/WO2012125408A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides compositions and methods for treating a disease or disorder associated with Apelin. Specifically, the invention relates to a pegylated form of Apelin to provide extended circulating life and inotropic effects, and thereby efficiently treat diseases or disorders associated with Apelin.
PCT/US2012/028298 2011-03-11 2012-03-08 Pegylated apelin and uses thereof WO2012125408A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2012229336A AU2012229336B2 (en) 2011-03-11 2012-03-08 Pegylated Apelin and uses thereof
EP12757055.4A EP2683360B1 (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof
SI201230560A SI2683360T1 (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof
CA2829693A CA2829693C (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof
DK12757055.4T DK2683360T3 (en) 2011-03-11 2012-03-08 PEGYLED APELIN AND APPLICATIONS THEREOF
US14/004,377 US20140142049A1 (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof
ES12757055.4T ES2573337T3 (en) 2011-03-11 2012-03-08 Pegylated Apelina and uses thereof
HRP20160547TT HRP20160547T1 (en) 2011-03-11 2016-05-23 Pegylated apelin and uses thereof
CY20161100447T CY1117654T1 (en) 2011-03-11 2016-05-24 POLYETHYLENE GLYCLENED APRELINE AND USES thereof
AU2017202919A AU2017202919B2 (en) 2011-03-11 2017-05-02 Pegylated Apelin and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161451623P 2011-03-11 2011-03-11
US61/451,623 2011-03-11

Publications (2)

Publication Number Publication Date
WO2012125408A1 WO2012125408A1 (en) 2012-09-20
WO2012125408A8 true WO2012125408A8 (en) 2018-01-25

Family

ID=46831054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/028298 WO2012125408A1 (en) 2011-03-11 2012-03-08 Pegylated apelin and uses thereof

Country Status (14)

Country Link
US (1) US20140142049A1 (en)
EP (2) EP3045183B1 (en)
AU (2) AU2012229336B2 (en)
CA (1) CA2829693C (en)
CY (1) CY1117654T1 (en)
DK (2) DK2683360T3 (en)
ES (2) ES2573337T3 (en)
HR (2) HRP20160547T1 (en)
HU (1) HUE027579T2 (en)
LT (1) LT3045183T (en)
PL (2) PL2683360T3 (en)
PT (1) PT3045183T (en)
SI (2) SI3045183T1 (en)
WO (1) WO2012125408A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3045183B1 (en) 2011-03-11 2018-07-04 Genzyme Corporation Pegylated apelin and uses thereof
ES2875957T3 (en) * 2012-12-20 2021-11-11 Amgen Inc APJ receptor agonists and their uses
JP6525951B2 (en) 2013-03-14 2019-06-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Apelin fusion protein and use thereof
JP6505691B2 (en) * 2013-07-25 2019-04-24 ノバルティス アーゲー Cyclic Apelin Derivatives for the Treatment of Heart Failure
WO2015013167A1 (en) * 2013-07-25 2015-01-29 Novartis Ag Disulfide cyclic polypeptides for the treatment of heart failure
US9340582B2 (en) * 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
CN105612172A (en) 2013-07-25 2016-05-25 诺华股份有限公司 Cyclic polypeptides for the treatment of heart failure
MX2016006709A (en) 2013-11-20 2016-09-08 Regeneron Pharma Aplnr modulators and uses thereof.
RU2697515C2 (en) 2014-03-25 2019-08-15 Лантхиопеп Б.В. Cyclic analogues of apelin
ES2950789T3 (en) * 2014-06-10 2023-10-13 Amgen Inc Apelin polypeptides
MA41580A (en) 2015-01-23 2017-11-29 Novartis Ag SYNTHETIC APELIN FATTY ACID CONJUGATES WITH IMPROVED HALF-LIFE
AU2017345493A1 (en) 2016-10-19 2019-05-02 Avive, Inc. Novel pegylated liposomal formulations of apelin for treatment of cardiovascular-related diseases
EP4168054A1 (en) * 2020-06-18 2023-04-26 Universite d'Aix Marseille Conjugated and labelled apelin, preparation and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6420339B1 (en) * 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
JP2006523209A (en) * 2003-03-12 2006-10-12 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Method for modulating angiogenesis by an apelin composition
US7947280B2 (en) * 2003-05-22 2011-05-24 The Board Of Trustees Of The Leland Stanford Junior University Apelin and uses thereof
EP1922336B1 (en) * 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
EP3045183B1 (en) 2011-03-11 2018-07-04 Genzyme Corporation Pegylated apelin and uses thereof

Also Published As

Publication number Publication date
EP3045183A1 (en) 2016-07-20
CA2829693A1 (en) 2012-09-20
EP2683360B1 (en) 2016-02-24
SI2683360T1 (en) 2016-06-30
US20140142049A1 (en) 2014-05-22
SI3045183T1 (en) 2018-11-30
AU2012229336B2 (en) 2017-02-02
DK3045183T3 (en) 2018-10-22
HRP20160547T1 (en) 2016-06-17
DK2683360T3 (en) 2016-05-30
AU2017202919B2 (en) 2019-03-14
EP3045183B1 (en) 2018-07-04
AU2012229336A1 (en) 2013-10-10
CA2829693C (en) 2020-04-21
AU2017202919A1 (en) 2017-05-25
WO2012125408A1 (en) 2012-09-20
HRP20181589T1 (en) 2018-12-28
LT3045183T (en) 2018-10-25
EP2683360A4 (en) 2014-09-03
PT3045183T (en) 2018-11-02
PL3045183T3 (en) 2018-12-31
ES2573337T3 (en) 2016-06-07
ES2690147T3 (en) 2018-11-19
HUE027579T2 (en) 2016-10-28
PL2683360T3 (en) 2016-09-30
EP2683360A1 (en) 2014-01-15
CY1117654T1 (en) 2018-03-07

Similar Documents

Publication Publication Date Title
WO2012125408A8 (en) Pegylated apelin and uses thereof
IL274469A (en) Compositions, uses and methods for treatment of metabolic disorders and diseases
WO2012177603A3 (en) Metalloenzyme inhibitor compounds
ECSP14013152A (en) METALOENZYM INHIBITING COMPOUNDS
IN2014DN00286A (en)
WO2011083150A3 (en) Obesity small molecules
IN2014MN01378A (en)
BR112013021366A2 (en) imidazo [5,1-f] [1,2,4] triazines for the treatment of neurological disorders
WO2011133875A3 (en) Metalloenzyme inhibitor compounds
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
IN2014DN06792A (en)
WO2012064943A3 (en) Metalloenzyme inhibitor compounds
WO2011163452A8 (en) Treating surface of the eye disorders
IL232710A0 (en) L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
WO2013023151A3 (en) Compositions and methods for treating celiac sprue disease
WO2012058529A3 (en) Metalloenzyme inhibitor compounds
MX2013015347A (en) Egfr targeted therapy.
WO2012082746A3 (en) Metalloenzyme inhibitor compounds
WO2013033004A3 (en) Metalloenzyme inhibitor compounds
WO2012123561A3 (en) Agent for prophylaxis and treatment of age-associated diseases and disorders and for prolonging life
WO2012136351A8 (en) Tapentadol for treating pain associated with trigeminal neuralgia
EP2701702A4 (en) Oxymetazoline for the treatment of ano-rectal disorders
HUE040124T2 (en) Topical compositions comprising diaminooxidase for the treatment or prevention of diseases associated with high histamine levels which involve an increase in pain
BR112015003815A2 (en) methods and compositions for treating a genetic condition
IL228973A (en) Oxymetazoline for the treatment of ano-rectal disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12757055

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2829693

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2012757055

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2012229336

Country of ref document: AU

Date of ref document: 20120308

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14004377

Country of ref document: US